<div class="table-wrap">
<div id="ehy310-T2" data-id="ehy310-T2" class="table-wrap-title">
<div class="label -label">Table 2</div>
<div class="caption"><p>Incidence
 rates (per 100 person years) and hazard ratios for cardiovascular 
endpoints and total mortality in CANTOS, according to the achievement of
 on-treatment interleukin-6 levels above or below the trial median of 
1.65 mg/L at 3 months among those allocated to canakinumab</p></div> </div>
<div class="table-overflow"><table>
<thead name="thead" align=""><tr>
<th>Treatment group, on-treatment IL-6 threshold </th>
<th>
<em>N</em> </th>
<th>Incidence rate (<em>n</em>)<a reveal-id="tblfn2" data-open="tblfn2" class="link link-ref link-reveal xref-fn"><sup>a</sup></a> </th>
<th>HR (95% CI) </th>
<th>
<em>P</em>-value </th>
<th>HR<a reveal-id="tblfn2" data-open="tblfn2" class="link link-ref link-reveal xref-fn"><sup>a</sup></a><sup>djusted</sup> (95% CI)<a reveal-id="tblfn3" data-open="tblfn3" class="link link-ref link-reveal xref-fn"><sup>b</sup></a> </th>
<th>
<em>P</em>-value </th>
</tr></thead>
<tbody>
<tr>
<td>MACE </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>4.91 (282) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>5.15 (291) </td>
<td>1.06 (0.90–1.25) </td>
<td>0.49 </td>
<td>0.90 (0.76–1.07) </td>
<td>0.25 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>3.21 (199) </td>
<td>0.64 (0.54–0.77) </td>
<td>&lt;0.0001 </td>
<td>0.68 (0.56–0.82) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>MACE+ </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>5.49 (311) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>5.44 (305) </td>
<td>1.00 (0.85–1.17) </td>
<td>0.97 </td>
<td>0.87 (0.74–1.02) </td>
<td>0.093 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>3.72 (228) </td>
<td>0.67 (0.57–0.80) </td>
<td>&lt;0.0001 </td>
<td>0.70 (0.59–0.84) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Cardiovascular mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>1.66 (103) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>2.26 (136) </td>
<td>1.38 (1.07–1.79) </td>
<td>0.0134 </td>
<td>1.15 (0.88–1.51) </td>
<td>0.30 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>0.72 (47) </td>
<td>0.43 (0.30–0.60) </td>
<td>&lt;0.0001 </td>
<td>0.48 (0.34–0.68) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>0.0002 </td>
</tr>
<tr>
<td>Total mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>2.86 (177) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>3.91 (235) </td>
<td>1.39 (1.14–1.69) </td>
<td>0.0010 </td>
<td>1.17 (0.96–1.44) </td>
<td>0.12 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>1.33 (87) </td>
<td>0.46 (0.36–0.60) </td>
<td>&lt;0.0001 </td>
<td>0.52 (0.40–0.68) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
</tbody>
</table></div>
<div content-id="ehy310-T2" class="table-modal"><table>
<thead name="thead" align=""><tr>
<th>Treatment group, on-treatment IL-6 threshold </th>
<th>
<em>N</em> </th>
<th>Incidence rate (<em>n</em>)<a reveal-id="tblfn2" data-open="tblfn2" class="link link-ref link-reveal xref-fn"><sup>a</sup></a> </th>
<th>HR (95% CI) </th>
<th>
<em>P</em>-value </th>
<th>HR<a reveal-id="tblfn2" data-open="tblfn2" class="link link-ref link-reveal xref-fn"><sup>a</sup></a><sup>djusted</sup> (95% CI)<a reveal-id="tblfn3" data-open="tblfn3" class="link link-ref link-reveal xref-fn"><sup>b</sup></a> </th>
<th>
<em>P</em>-value </th>
</tr></thead>
<tbody>
<tr>
<td>MACE </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>4.91 (282) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>5.15 (291) </td>
<td>1.06 (0.90–1.25) </td>
<td>0.49 </td>
<td>0.90 (0.76–1.07) </td>
<td>0.25 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>3.21 (199) </td>
<td>0.64 (0.54–0.77) </td>
<td>&lt;0.0001 </td>
<td>0.68 (0.56–0.82) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>MACE+ </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>5.49 (311) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>5.44 (305) </td>
<td>1.00 (0.85–1.17) </td>
<td>0.97 </td>
<td>0.87 (0.74–1.02) </td>
<td>0.093 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>3.72 (228) </td>
<td>0.67 (0.57–0.80) </td>
<td>&lt;0.0001 </td>
<td>0.70 (0.59–0.84) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>Cardiovascular mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>1.66 (103) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>2.26 (136) </td>
<td>1.38 (1.07–1.79) </td>
<td>0.0134 </td>
<td>1.15 (0.88–1.51) </td>
<td>0.30 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>0.72 (47) </td>
<td>0.43 (0.30–0.60) </td>
<td>&lt;0.0001 </td>
<td>0.48 (0.34–0.68) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>0.0002 </td>
</tr>
<tr>
<td>Total mortality </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Placebo </td>
<td>1597 </td>
<td>2.86 (177) </td>
<td>1 (ref) </td>
<td> </td>
<td>1 (ref) </td>
<td> </td>
</tr>
<tr>
<td> Canakinumab, IL-6 ≥ median value (1.65 mg/L) </td>
<td>1619 </td>
<td>3.91 (235) </td>
<td>1.39 (1.14–1.69) </td>
<td>0.0010 </td>
<td>1.17 (0.96–1.44) </td>
<td>0.12 </td>
</tr>
<tr>
<td> Canakinumab, IL-6 &lt; median value (1.65 mg/L) </td>
<td>1617 </td>
<td>1.33 (87) </td>
<td>0.46 (0.36–0.60) </td>
<td>&lt;0.0001 </td>
<td>0.52 (0.40–0.68) </td>
<td>&lt;0.0001 </td>
</tr>
<tr>
<td>  <em>P</em>-value for trend across categories </td>
<td> </td>
<td> </td>
<td> </td>
<td>&lt;0.0001 </td>
<td> </td>
<td>&lt;0.0001 </td>
</tr>
</tbody>
</table></div>
<div class="table-wrap-foot">
<div content-id="tblfn2"><div class="fn">
<div class="label -label">a</div>
<p>Per 100 person-years of exposure.</p>
</div></div>
<div content-id="tblfn3"><div class="fn">
<div class="label -label">b</div>
<p>Covariates
 included in the adjusted multivariable model include age, gender, 
smoking status, hypertension, diabetes, body mass index, baseline level 
of IL-6, and baseline level of LDL cholesterol.</p>
</div></div>
<div content-id="tblfn4"><div class="fn"><p>The median percent reduction in IL-6 at 3 months was −34.9.</p></div></div>
</div>
</div>